Aphaia Pharma has reported encouraging results from its early clinical trials of its coated glucose microbeads that treat obesity and metabolic dysfunction.

The findings, published in the journal Diabetes, Obesity and Metabolism, highlight how the company’s coated glucose microbeads can trigger a broad hormonal response in the gut, improve glucose handling, and do so with a favorable safety profile. Aphaia continues to test its lead formulation in a larger Phase II trial focused specifically on individuals with obesity. Topline results from that study are expected in the third quarter of 2026.

The Swiss/US-based company’s lead formulation, known as APH-012, leverages nutrient-sensing cells in the distal small intestine to trigger a broad endogenous hormonal response that regulates appetite, glucose metabolism, and satiety.

Dr. Steffen-Sebastian Bolz, Aphaia’s chief scientific officer, said the results underscore the potential for a more natural intervention. “Unlike incretin mimetics, our approach harnesses nutrient-sensing cells in the gut to elicit a broad and targeted endogenous response, resulting in comparable efficacy with far fewer side effects,” he noted.

Phase I Data

The Phase I program involved two studies (NCT05713773 and NCT05737927) in individuals with obesity, each conducted under fasting conditions. These trials were primarily designed to examine how the drug was absorbed and how it affected metabolic responses, including hormone release.

Results showed that the microbeads reached the distal small intestine as intended, avoiding the excessive glucose absorption that would typically occur in the upper gut. Once released, the formulation triggered the secretion of a wide spectrum of enteric hormones, including glucagon-like peptide-1 (GLP-1), GLP-2, peptide tyrosine-tyrosine (PYY), oxyntomodulin, glicentin, and glucose-dependent insulinotropic peptide (GIP). Importantly, the hormonal response was consistent across participants, with little variability between individuals.

The timing of hormone release also mirrored the body’s natural rhythm. Levels began to rise around 90 minutes after ingestion, similar to what would be seen after a meal,and remained elevated for four to six hours. This prolonged response was attributed to the slow, continuous release of glucose from the beads. Beyond gut hormones, the treatment also stimulated insulin and C-peptide release from the pancreas, adding further evidence of its systemic metabolic effects.

Phase II Data

Encouraged by the Phase I findings, Aphaia advanced to a randomized, double-blind, placebo-controlled Phase IIa trial (NCT05803772) that evaluated the safety and efficacy of APH-012 in a broader patient group.

The study enrolled 30 adults, including healthy individuals, prediabetic patients, and those with diabetes, and used a crossover design to compare six weeks of treatment with either the oral formulation or a placebo.

In participants with prediabetes, the results were striking. After six weeks of treatment, glucose tolerance improved significantly. The average two-hour glucose level during an oral glucose tolerance test (OGTT) fell from 8.72 mmol/L to 6.76 mmol/L. By contrast, those on placebo showed no meaningful change. The overall glucose exposure, measured by the OGTT area under the curve, also improved compared to the treatment group.

Safety was another key outcome. Across the trial, adverse events were infrequent and mild, suggesting the therapy was well tolerated.

Dr. Christian Sina, director of the Institute of Nutritional Medicine at the University of Luebeck in Germany and principal investigator of the trial, emphasized the broader implications. “Given the benign safety profile and the broad metabolic effects, this oral formulation presents a sustainable alternative for obesity and related diseases,” he said.

The Obesity Landscape

The global market for obesity treatments has grown quickly in recent years, driven by the success of Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide). In 2024, Novo Nordisk’s weight loss drugs Wegovy and Saxenda (liraglutide) earned DKK65.1 billion ($9 billion) in sales. However, they face strong competition from Eli Lilly’s Zepbound (tirzepatide), a dual GLP-1 and GIP receptor agonist, which achieved $4.9 billion in sales that year.

This competitive landscape has also led to a surge in deals. In March, Roche signed a $5.3 billion co-development agreement with Zealand Pharma for an  amylin analog, petrelintide. AbbVie acquired Gubra’s obesity drug for $2.2 billion. More recently, Novo Nordisk collaborated with Septerna in a $2.2 billion partnership to develop oral small molecules targeting obesity and cardiometabolic diseases.